Alpha Tau Medical Ltd. (DRTS)
| Market Cap | 1.35B +371.7% |
| Revenue (ttm) | n/a |
| Net Income | -92.57M |
| EPS | -1.05 |
| Shares Out | 92.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 475,218 |
| Open | 14.76 |
| Previous Close | 14.81 |
| Day's Range | 14.45 - 14.90 |
| 52-Week Range | 3.18 - 15.10 |
| Beta | 1.18 |
| Analysts | Buy |
| Price Target | 14.40 (-1.64%) |
| Earnings Date | Aug 10, 2026 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the trea... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for DRTS stock is "Buy." The 12-month stock price target is $14.4, which is a decrease of -1.64% from the latest price.
News
Alpha Tau price target raised to $16 from $15 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Alpha Tau (DRTS) to $16 from $15 and keeps a Buy rating on the shares post the Q2 report. The U.S. pivotal…
Alpha Tau reports Q2 EPS (25c), consensus (14c)
“The second quarter of 2026 was without question the busiest and most consequential period in Alpha Tau’s (DRTS) history, and the momentum has only continued to accelerate since,” said Alpha…
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, to...
Alpha Tau reports Alpha DaRT combination study results
Alpha Tau (DRTS) announced results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell ca...
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab...
Alpha Tau treats first patient in ADMIRE study for recurrent skin cancer
Alpha Tau (DRTS) Medical announced the successful treatment of the first patient in its ADMIRE study, a clinical trial evaluating intratumoral Alpha DaRT for immunocompromised patients with recurrent ...
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson
Alpha Tau treats first glioblastoma patient in Israel with Alpha DaRT
Alpha Tau (DRTS) announced the treatment with Alpha DaRT of the first glioblastoma patient in Israel, and the first ever outside of the United States, performed at Hadassah University Medical…
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah Medical Center in Israel
Alpha Tau gets FDA clearance to complete enrollment in REGAIN trial
Alpha Tau (DRTS) announced that the FDA has cleared the company to proceed with enrollment of the final seven patients in its U.S. REGAIN trial, following the FDA’s review of…
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau price target raised to $17 from $15 at Barclays
Barclays raised the firm’s price target on Alpha Tau (DRTS) to $17 from $15 and keeps an Overweight rating on the shares. The company’s Tolmar commercialization deal provides revenue “optionality,”…
Alpha Tau, Tolmar announce strategic collaboration agreement
Alpha Tau (DRTS) and Tolmar announced a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer in the United States. Through the collaboration, ...
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates ...
Alpha Tau reports positive survival data from pancreatic cancer study
Alpha Tau (DRTS) announced positive overall survival and safety results from a pooled analysis of three prospective Phase 1/2 clinical studies evaluating its Alpha DaRT therapy in patients with locall...
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of thre...
Alpha Tau Medical Transcript: Lytham Partners Spring 2026 Investor Conference
Major clinical trials in skin, pancreatic, and brain cancers are advancing, with key data expected by year-end. Combination studies show promising immune responses, and regulatory progress continues in the U.S., Israel, and Japan. $80M in cash supports milestones through 2026.
Alpha Tau initiated with an Overweight at Barclays
Barclays initiated coverage of Alpha Tau (DRTS) with an Overweight rating and $15 price target Alpha Tau is a biomedical company developing its Alpha DaRT radiotherapeutic implant for the treatment…
Alpha Tau price target raised to $8 from $5 at Piper Sandler
Piper Sandler raised the firm’s price target on Alpha Tau (DRTS) to $8 from $5 and keeps a Neutral rating on the shares after the company reported Q1 results, including…
Alpha Tau reports Q1 EPS (12c), consensus (12c)
“The first quarter of 2026 has been a truly defining period for Alpha Tau (DRTS), reflecting the convergence of two powerful dynamics that have been years in the making: the…
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of pat...
Alpha Tau Medical Earnings release: Q1 2026
Alpha Tau Medical released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, to...
Alpha Tau Medical Slides: Investor presentation
Alpha Tau Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Alpha Tau price target raised to $14 from $12 at Ladenburg
Ladenburg raised the firm’s price target on Alpha Tau (DRTS) to $14 from $12 and keeps a Buy rating on the shares after the company announced interim results from the…